Closed
The Marked Chart Wire · Health
Evaxion
The biotech firm disclosed new Phase 2 findings for its personalized vaccine, EVX-01. The data indicated robust immune reactions and validated its AI-Immunology platform.
New to this? Read: Reading a stock chart
FDA Approval
The FDA has approved daraxonrasib from Revolution Medicines for the treatment of pancreatic cancer.
Novartis
Novartis is said to be discontinuing a heart medication developed with Ionis following a late-stage clinical trial failure.
J&J Psoriasis Drug
Johnson & Johnson announced positive results from a late-stage trial of its oral medication for plaque psoriasis and psoriatic arthritis.
Wegovy
Novo Nordisk presented real-world results showing that semaglutide 2.4 mg improved liver markers, body weight, and glucose levels in adults with MASH. The drug outperformed resmetirom in reducing AST and other cardiometabolic indicators.
Measles
American health officials report over 5,000 confirmed measles cases, the most recorded in three and a half decades.
Cognition
Cognition outlined a plan to begin Phase III trials for DLB in mid-2027. The company stated it has sufficient cash to operate through the fourth quarter of 2027.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.